Introducing PagStream® – Enabling Brazilian-Based Retailers to Create Subscription Services, Guaranteeing Predictable Revenue for Multiple Industries
June 17, 2024 08:00 ET
|
PagBrasil
SÃO PAULO, Brazil, June 17, 2024 (GLOBE NEWSWIRE) -- PagBrasil, a leading fintech company that processes digital payments for businesses worldwide, today announced an updated version of its...
Kymera Therapeutics Presents New Clinical Data from the Ongoing Phase 1 Trial of STAT3 Degrader KT-333 at EHA Annual Meeting
June 14, 2024 07:00 ET
|
Kymera Therapeutics, Inc.
KT-333 demonstrated initial clinical proof of concept across multiple hematological malignancies, including complete responses in two patients with Hodgkin’s lymphoma Robust STAT3 knockdown and...
MEF and TM Forum Unify APIs and Service Models to Automate Ecosystem for MEF NaaS Services
June 12, 2024 09:06 ET
|
MEF
MEF, TM Forum collaborate to deliver powerful integrated automation solution to advance enterprise digital services with industry-wide standardization.
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
June 11, 2024 16:05 ET
|
Neurona Therapeutics
Neurona Therapeutics Appoints Dr. Manher Joshi as Chief Medical Officer
WellSpan Health Partners with Jersey College to Establish a Dedicated School of Nursing in South Central Pennsylvania
June 11, 2024 09:41 ET
|
WellSpan Health
York, Pa., June 11, 2024 (GLOBE NEWSWIRE) -- WellSpan Health and Jersey College, an accredited post-secondary institution specializing in nursing education, have received regulatory approval to...
Tiziana Life Sciences Submits Grant Application to ALS Association to Fund Clinical Trial of Intranasal Foralumab
June 04, 2024 09:00 ET
|
Tiziana Life Sciences Ltd.
NEW YORK, June 04, 2024 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...
Kymera Therapeutics Presents New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
June 01, 2024 08:00 ET
|
Kymera Therapeutics, Inc.
KT-253 demonstrates initial clinical proof of concept in patients with tumor types shown to be sensitive in preclinical models, including responses in MCC and AML Evidence of target engagement...
There’s a New Emperor in Town: Marcus-Aurelius Empowers SMBs to Achieve Digital Success with Expert Website Design and Strategic Consulting
May 31, 2024 09:00 ET
|
Marcus Aurelius: Digital
London, UK, May 31, 2024 (GLOBE NEWSWIRE) -- Marcus-Aurelius, known by Marc-Aurele, is transforming the digital landscape for startups and medium-sized businesses (SMBs) by announcing a...
Kymera Therapeutics to Present New Clinical Data from Ongoing Phase 1 Trial of MDM2 Degrader KT-253 at ASCO Annual Meeting
May 23, 2024 17:00 ET
|
Kymera Therapeutics, Inc.
Abstract released today highlights safety, pharmacodynamic and clinical response data with additional data to be presented in a poster session on June 1, 2024 KT-253 Phase 1 study ongoing with...
A Bold Step Forward: Trial Equity and Miller Tanner Associates Partner to Champion Diversity in Clinical Research
May 22, 2024 10:23 ET
|
Trial Equity
Trial Equity and Miller Tanner Associates are partnering to expand clinical trial participation to address the gap in diversity.